Back to Search
Start Over
Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors.
- Source :
-
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia [Rev Bras Ginecol Obstet] 2019 Jul; Vol. 41 (7), pp. 440-448. Date of Electronic Publication: 2019 Jul 25. - Publication Year :
- 2019
-
Abstract
- Objective: To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs).<br />Methods: Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017.<br />Results: The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred.<br />Conclusion: Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.<br />Competing Interests: The authors have no conflicts of interests to declare.<br /> (Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil.)
- Subjects :
- Adolescent
Adult
Aged
Brazil epidemiology
Female
Humans
Middle Aged
Neoplasm Recurrence, Local mortality
Neoplasm Recurrence, Local therapy
Ovarian Neoplasms mortality
Ovarian Neoplasms therapy
Prognosis
Retrospective Studies
Sertoli-Leydig Cell Tumor mortality
Sertoli-Leydig Cell Tumor therapy
Young Adult
Neoplasm Recurrence, Local epidemiology
Ovarian Neoplasms epidemiology
Sertoli-Leydig Cell Tumor epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1806-9339
- Volume :
- 41
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia
- Publication Type :
- Academic Journal
- Accession number :
- 31344718
- Full Text :
- https://doi.org/10.1055/s-0039-1693056